Non-for-profit org Viva Physicians said yesterday that it will lead a pan-industry effort to study the use of paclitaxel-eluting devices for the treatment of peripheral artery disease in above-the-knee applications.
The initiative comes on the heels of a meta-analysis published in the Journal of the American Heart Association this month showing a potential link between increased long-term mortality outcomes and paclitaxel devices.
Companies with commercial drug-coated balloons and drug-eluting stents, including Medtronic (NYSE:MDT), Boston Scientific (NYSE:BSX) and Philips (NYSE:PHG), have agreed to give Viva de-identified, patient-level data from clinical programs.
“Due to recent discussion around the safety of paclitaxel-eluting devices, both Viva and our industry partners firmly believe in the need for an analysis of this nature to better address some of these concerns,” Dr. Krishna Rocha-Singh, a co-founding member of Viva’s board, said in prepared remarks. “We are all committed to working together in a transparent, timely, and defined manner and look forward to making this research publicly available to the clinical community.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.